Invesco Ltd. Boosts Stock Holdings in AngioDynamics, Inc. (NASDAQ:ANGO)

Invesco Ltd. boosted its stake in AngioDynamics, Inc. (NASDAQ:ANGO) by 1.2% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 119,249 shares of the medical instruments supplier’s stock after purchasing an additional 1,451 shares during the quarter. Invesco Ltd. owned about 0.29% of AngioDynamics worth $1,092,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in ANGO. Segall Bryant & Hamill LLC increased its holdings in shares of AngioDynamics by 55.3% in the 4th quarter. Segall Bryant & Hamill LLC now owns 1,415,156 shares of the medical instruments supplier’s stock worth $12,963,000 after buying an additional 503,713 shares during the last quarter. Royce & Associates LP raised its position in AngioDynamics by 13.5% during the fourth quarter. Royce & Associates LP now owns 1,119,385 shares of the medical instruments supplier’s stock valued at $10,254,000 after purchasing an additional 133,312 shares during the period. Geode Capital Management LLC lifted its stake in shares of AngioDynamics by 1.4% in the 4th quarter. Geode Capital Management LLC now owns 974,302 shares of the medical instruments supplier’s stock valued at $8,927,000 after purchasing an additional 13,535 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of AngioDynamics by 46.0% in the 4th quarter. JPMorgan Chase & Co. now owns 807,483 shares of the medical instruments supplier’s stock worth $7,397,000 after purchasing an additional 254,322 shares during the period. Finally, First Eagle Investment Management LLC boosted its holdings in shares of AngioDynamics by 4.1% in the 4th quarter. First Eagle Investment Management LLC now owns 410,335 shares of the medical instruments supplier’s stock worth $3,759,000 after purchasing an additional 16,221 shares during the period. Institutional investors own 89.43% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price target (up previously from $15.00) on shares of AngioDynamics in a research note on Monday, April 7th.

AngioDynamics Stock Performance

Shares of ANGO stock opened at $9.19 on Friday. The stock’s fifty day moving average is $9.48 and its two-hundred day moving average is $9.20. The firm has a market capitalization of $373.18 million, a P/E ratio of -1.63 and a beta of 0.52. AngioDynamics, Inc. has a fifty-two week low of $5.47 and a fifty-two week high of $13.50.

AngioDynamics (NASDAQ:ANGO) last posted its earnings results on Wednesday, April 2nd. The medical instruments supplier reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.16. The company had revenue of $72.00 million during the quarter, compared to analysts’ expectations of $70.30 million. AngioDynamics had a negative return on equity of 7.26% and a negative net margin of 79.38%. The company’s revenue for the quarter was down 4.3% on a year-over-year basis. On average, equities analysts forecast that AngioDynamics, Inc. will post -0.37 earnings per share for the current year.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.